Adalimumab and myositis: a case report and review of the French and international Pharmacovigilance databases


Since the early 2000s, TNFα inhibitors have revolutionized the treatment of inflammatory rheumatologic disease and chronic inflammatory bowel disease such as Crohn’s disease [1,2]. TNFα is a pro-inflammatory cytokine with multiple pleiotropic effects including apoptosis, cellular proliferation and pro-inflammatory cytokines production [3]. It has been implicated in various auto-immune diseases. Anti-TNFα therapies have demonstrated their consistent and remarkable efficacy in controlling signs and symptoms, with a favorable safety profile [4].


Leave A Reply